<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0002863'>Myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) are <z:hpo ids='HP_0001425'>heterogeneous</z:hpo> diseases </plain></SENT>
<SENT sid="1" pm="."><plain>Patients with blast counts of more than 20% of nucleated bone marrow cells have a high risk of short survival </plain></SENT>
<SENT sid="2" pm="."><plain>We treated six patients with <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess of blast in transformation (RAEBiT) with low dose <z:chebi fb="1" ids="16040">cytosine</z:chebi> <z:chebi fb="0" ids="22601">arabinoside</z:chebi> (LD Ara-C) </plain></SENT>
<SENT sid="3" pm="."><plain>We had one partial remission (PR), surviving 16 weeks and two complete remissions (CR), surviving 22 and 55+ months </plain></SENT>
<SENT sid="4" pm="."><plain><z:e sem="disease" ids="C0854467" disease_type="Disease or Syndrome" abbrv="">Myelosuppression</z:e> was dominant in <z:hpo ids='HP_0000001'>all</z:hpo> patients, but was not as serious as with conventional remission-induction treatments for <z:hpo ids='HP_0001909'>leukemias</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>Bone marrow <z:mpath ids='MPATH_58'>aplasia</z:mpath> occurred in <z:hpo ids='HP_0000001'>all</z:hpo> responding patients, but a differentiation effect is possible too </plain></SENT>
<SENT sid="6" pm="."><plain>Maintenance therapy with LD Ara-C may be important for the two long-lasting CR </plain></SENT>
</text></document>